24小时在线观看视频免费,avtt天堂网久久精品,色婷婷狠狠97成为人免费

Combined Clostridium Butyricum and Bifidobacterium Powder/Capsule, Live (CHANG LEKANG) is a combination of clostridium butyricunm and bifidobacterium infantis. Both bacterial strains are dominant in autochthonous intestinal flora and can synergistically promote the growth of each other. With proven immunoregulatory effect and a wide range of clinical applications and evidence-based support, it is a probiotic that is explicitly approved for use by the old and the young, as well as pregnant women before and after delivery, in the package insert.

【Indications】

Acute and chronic diarrhea caused by acute non-specific infection, intestinal flora imbalance caused by antibiotics, chronic liver disease and other reasons, and related acute and chronic diarrhea and dyspepsia.

【R&D and Commercial Production of CLOBICO】

In 1996, Clostridium butyricum and Bifidobacterium infantis were screened and obtained;

In 1997, the strains were deposited in the China General Microbiological Culture Collection Center;

In 1999, the clinical trial approval was obtained, and the phase I, II and III clinical trials were initiated;

In 2001, the new drug certificate was obtained;

In 2002, the production approval was obtained;

In 2008, the stability study of cold-chain transportation under intermittent ambient temperature was carried out;

In 2009, the filing of intermittent temperature during cold-chain transportation was completed, and the package insert was noted that "in case of intermittent refrigeration temperature during transportation, the shelf life should not exceed 7 days, and light and heat should be avoided".

In 2010, a multicenter randomized controlled clinical trial of Combined Clostridium Butyricum and Bifidobacterium Powder in the prevention of antibiotic-associated diarrhea in children with pneumonia was carried out, and the results confirmed that: Combined Clostridium Butyricum and Bifidobacterium Powder could effectively reduce the risk of AAD in hospitalized children with pneumonia, and the incidence of AAD in the test group was 7.8% (13/193) within 7 days of observation;